06:52 AM EDT, 08/18/2025 (MT Newswires) -- Bristol-Myers Squibb Company ( BMY ) and SystImmune said Monday that the US Food and Drug Administration has granted Breakthrough Therapy Designation to izalontamab brengitecan to treat certain types of non-small cell lung cancer patients.

The drug is being jointly developed by the two companies under a collaboration and exclusive license agreement outside of China.

The decision was based on data from three ongoing clinical trials, which showed evidence of improved efficacy with a manageable safety profile in the targeted patients, the companies said.